Loading...
XJPX4582
Market cap54mUSD
Jan 23, Last price  
184.00JPY
1D
-2.65%
1Q
-18.58%
Jan 2017
-81.15%
IPO
-86.06%
Name

SymBio Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XJPX:4582 chart
P/E
—
P/S
1.51
EPS
—
Div Yield, %
—
Shrs. gr., 5y
19.13%
Rev. gr., 5y
7.82%
Revenues
5.59b
-44.15%
1,630,029,0001,191,127,0001,449,972,0001,882,521,0001,955,178,0001,532,054,0001,955,027,0001,933,241,0002,368,112,0003,444,206,0003,835,530,0002,837,753,0002,987,051,0008,252,582,00010,008,338,0005,589,708,000
Net income
-1.96b
L
20,987,000-217,872,000-642,307,000-2,104,513,000-1,733,320,000-1,605,224,000-1,115,877,000-2,632,095,000-2,313,233,000-3,977,862,000-2,752,533,000-4,376,258,000-4,090,216,0002,032,203,0001,179,238,000-1,962,817,000
CFO
-195m
L
154,387,000-211,336,000-753,971,000-2,074,057,000-1,658,588,000-1,677,348,000-1,266,174,000-2,271,686,000-1,960,089,000-3,816,793,000-2,324,547,000-4,350,738,000-4,122,483,000140,042,0001,614,241,000-194,685,000

Profile

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
URL
https://www.symbiopharma.com/
IPO date
Oct 20, 2011
Employees
122
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,589,708
-44.15%
10,008,338
21.28%
Cost of revenue
4,883,928
6,566,233
Unusual Expense (Income)
NOPBT
705,780
3,442,105
NOPBT Margin
12.63%
34.39%
Operating Taxes
767,429
927,041
Tax Rate
108.73%
26.93%
NOPAT
(61,649)
2,515,064
Net income
(1,962,817)
-266.45%
1,179,238
-41.97%
Dividends
Dividend yield
Proceeds from repurchase of equity
681,157
614,225
BB yield
-6.91%
-2.41%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
(6,991,336)
Net debt
(6,604,007)
(6,367,554)
Cash flow
Cash from operating activities
(194,685)
1,614,241
CAPEX
(232,797)
(47,558)
Cash from investing activities
(376,696)
(47,127)
Cash from financing activities
680,160
627,985
FCF
570,974
2,794,989
Balance
Cash
6,517,007
6,282,554
Long term investments
87,000
85,000
Excess cash
6,324,522
5,867,137
Stockholders' equity
(10,899,611)
(8,929,112)
Invested Capital
18,113,229
10,042,801
ROIC
25.59%
ROCE
9.78%
42.45%
EV
Common stock shares outstanding
39,902
39,605
Price
247.00
-61.59%
643.00
-43.84%
Market cap
9,855,856
-61.30%
25,466,276
-42.74%
EV
3,251,849
19,098,722
EBITDA
801,785
3,540,197
EV/EBITDA
4.06
5.39
Interest
11,478
249,054
Interest/NOPBT
1.63%
7.24%